We were particularly interested in the performance of EGFR testing in our NGS assay, because mutations in this gene may be therapeutically targetable, and because it is often challenging to analyze, as DNA degradation and low tumor percentage are frequently encountered in lung cancer specimens. This evidence concerns the gene EGFR and lung cancer.